ResMed Inc stock (AU000000RMD6): ex-dividend date approaches May 14

ResMed Inc goes ex-dividend on May 14, 2026, with a payout of 0.6 USD per share payable June 18. The NYSE-listed medical device maker saw its shares rise 2.53% to $203.79 on May 12.

ResMed Inc shareholders have a final chance to capture the upcoming dividend before the ex-dividend date on May 14, 2026. The company will pay 0.6 USD per share on June 18, 2026, to those on record by that date, according to Moomoo as of May 12, 2026. Separately, ResMed Inc stock gained 2.53% on May 12, closing at $203.79 after starting at $198.76, per StockInvest.us as of May 12, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Healthcare / Medical Devices
• Headquarters/country: United States
• Core markets: United States and international
• Key revenue drivers: Sleep apnea devices, cloud software
• Home exchange/listing venue: NYSE (RMD)
• Trading currency: USD

ResMed Inc: core business model

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications focused on diagnosing, treating, and managing respiratory disorders, primarily in the United States and internationally, according to Simply Wall St. The company operates in two main segments: Sleep and Breathing Health, and Residential Care Software. Products include sleep apnea diagnostic devices like ApneaLink Air, NightOwl, and EasyCare Tx for use in clinics, hospitals, and homes.

Main revenue and product drivers for ResMed Inc

ResMed Inc generates revenue through its portfolio of devices for sleep apnea diagnosis and titration, including portable tools measuring oximetry, respiratory effort, and airflow. The Sleep and Breathing Health segment drives core sales, with cloud-connected solutions enhancing patient management. Residential Care Software supports additional revenue streams via digital platforms for care delivery.

Industry trends and competitive position

The sleep apnea market continues to expand due to rising awareness of respiratory health issues in the US, where ResMed Inc holds a strong position with innovative diagnostics. Its market cap stood at approximately $29.71 billion as of the latest NYSE close at $203.92, per MarketBeat.

Why ResMed Inc matters for US investors

Listed on the NYSE, ResMed Inc offers US investors exposure to the growing medical device sector, particularly sleep health solutions amid an aging population and increasing obesity rates driving demand for apnea treatments.

Conclusion

ResMed Inc approaches its ex-dividend date on May 14, 2026, with a 0.6 USD payout, while recent share price gains reflect market interest in its respiratory health portfolio. The company's focus on sleep apnea devices positions it well in a key US healthcare niche, though investors monitor broader sector dynamics. Ongoing product innovation supports its competitive stance amid evolving demand.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.